In vivo modulatory effects of chitooligosaccharide nanoparticles on mouse serum cytokines and splenocytes

Journal of Experimental Nanoscience

Volumn 9, Issue 8, 2014, Pages 860-870

  Lin, Yi Sheng ^a   Wu, Ming Fang ^a   Takamori, Yoshimori ^a   Okamoto, Yoshiharu ^a   Minami, Saburo ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

chitooligosaccharide; chitosan; cytokine; lymphocyte; nanoparticles

Indexed keywords

BIOMEDICAL ENGINEERING; CELL CULTURE; CELLS; CHITOSAN; LYMPHOCYTES; MAMMALS; T-CELLS;

BIOMEDICAL MATERIAL; CELL-MEDIATED IMMUNE; CHITOOLIGOSACCHARIDES; CYTOKINES; INHIBITORY EFFECT; POLYELECTROLYTE COMPLEXES; SPLENIC LYMPHOCYTE; WATER-SOLUBLE CHITOSAN;

NANOPARTICLES;

CARBOXYMETHYL CHITOSAN CHITOOLIGOSACCHARIDE NANOPARTICLE; CHITOSAN DERIVATIVE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NANOPARTICLE; OLIGOSACCHARIDE; SULPHATED CHITOSAN CHITOOLIGOSACCHARIDE NANOPARTICLE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CD19+ B CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FIBROBLAST CULTURE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA CELL LINE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN LYMPHOCYTE;

EID: 84902653123     PISSN: 17458080     EISSN: 17458099     Source Type: Journal    
DOI: 10.1080/17458080.2012.733078     Document Type: Article

References (30)

1. Kong, M, Chen, XG, Xing, K and Park, HJ. 2010. Antimicrobial properties of chitosan and mode of action: A state of the art review. Int. J. Food Microbiol., 144: 51 - 63.
2. Muzzarelli, RA. 2010. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar. Drugs, 8: 292 - 312.
3. Wang, JJ, Zeng, ZW, Xiao, RZ, Xie, T, Zhou, GL, Zhan, XR and Wang, SL. 2011. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine, 6: 765 - 774.
4. Harish Prashanth, KV and Tharanathan, RN. 2007. Chitin/chitosan: Modifications and their unlimited application potential{box drawings light horizontal}an overview. Trends Food Sci. Technol., 18: 117 - 131.
5. Aam, BB, Heggset, EB, Norberg, AL, Sorlie, M, Varum, KM and Eijsink, VG. 2010. Production of chitooligosaccharides and their potential applications in medicine. Mar. Drugs, 8: 1482 - 1517.
6. Qiao, Y, Bai, XF and Du, YG. 2011. Chitosan oligosaccharides protect mice from LPS challenge by attenuation of inflammation and oxidative stress. Int. Immunopharmacol., 11: 121 - 127.
7. Park, JK, Chung, MJ, Choi, HN and Park, YI. 2011. Effects of the molecular weight and the degree of deacetylation of chitosan oligosaccharides on antitumor activity. Int. J. Mol. Sci., 12: 266 - 277.
8. Luo, Q, Zhao, J, Zhang, X and Pan, W. 2011. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm., 403: 185 - 191.
9. Qu, G, Yao, Z, Zhang, C, Wu, X and Ping, Q. 2009. PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. Eur. J. Pharm. Sci., 37: 98 - 105.
10. Sahu, SK, Mallick, SK, Santra, S, Maiti, TK, Ghosh, SK and Pramanik, P. 2010. In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J. Mater. Sci.: Mater. Med., 21: 1587 - 1597.
11. Sayin, B, Somavarapu, S, Li, XW, Thanou, M, Sesardic, D, Alpar, HO and Senel, S. 2008. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int. J. Pharm., 363: 139 - 148.
12. Zhang, YF, Yin, P, Zhao, XQ, Wang, J, Wang, CD, Ren, L and Zhang, QQ. 2009. O-Carboxymethyl-chitosan/organosilica hybrid nanoparticles as non-viral vectors for gene delivery. Mater. Sci. Eng. C: Mater Bio. Appl., 29: 2045 - 2049.
13. Zhang, J, Chen, XG, Sun, GZ, Huang, L and Cheng, XJ. 2010. Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin. Colloids Surf. B: Biointerfaces, 77: 125 - 130.
14. Hoang, TM and Eichenfield, LF. 2000. The rising incidence of melanoma in children and adolescents. Dermatol. Nurs., 12: 188 - 189.
15. Krause, DR, Piva, TJ, Brown, SB and Ellem, KA. 1997. Characterization and localization of mitochondrial oligopeptidase (MOP) (EC3.4.24.16) activity in the human cervical adenocarcinoma cell line HeLa. J. Cell. Biochem., 66: 297 - 308.
16. Muzzarelli, RA, Tanfani, F, Emanuelli, M and Mariotti, S. 1982. (Carboxymethylidene) chitosans and N-(Carboxymethyl)-chitosans - Novel chelating polyampholytes obtained from chitosan glyoxylate. Carbohydr. Res., 107: 199 - 214.
17. Zhou, H, Qian, J, Wang, J, Yao, W, Liu, C, Chen, J and Cao, X. 2009. Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N, 6-O-sulfated chitosan in vitro and in vivo. Biomaterials, 30: 1715 - 1724.
18. Lin, YS, Radzi, R, Morimoto, M, Saimoto, H, Okamoto, Y and Minami, S. Characterization of chitosan-carboxymethyl dextran nanoparticles as a drug carrier and as a stimulator of mouse splenocytes, J. Biomater Sci. Polym. Ed. (2011), in press
19. Nishimura, K, Nishimura, S, Seo, H, Nishi, N, Tokura, S and Azuma, I. 1987. Effect of multiporous microspheres derived from chitin and partially deacetylated chitin on the activation of mouse peritoneal macrophages. Vaccine, 5: 136 - 140.
20. Xu, Y and Du, Y. 2003. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm., 250: 215 - 226.
21. Nasti, A, Zaki, NM, Leonardis, P, Ungphaiboon, S, Sansongsak, P, Rimoli, MG and Tirelli, N. 2009. Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: Systematic optimisation of the preparative process and preliminary biological evaluation. Pharm. Res., 26: 1918 - 1930.
22. Wang, R, Huang, J, Wei, M and Zeng, X. 2010. The synergy of 6-O-sulfation and N- or 3-O-sulfation of chitosan is required for efficient inhibition of P-selectin-mediated human melanoma A375 cell adhesion. Biosci. Biotechnol. Biochem., 74: 1697 - 1700.
23. Shen, KT, Chen, MH, Chan, HY, Jeng, JH and Wang, YJ. 2009. Inhibitory effects of chitooligosaccharides on tumor growth and metastasis. Food Chem. Toxicol., 47: 1864 - 1871.
24. Shibata, Y, Foster, LA, Kurimoto, M, Okamura, H, Nakamura, RM, Kawajiri, K, Justice, JP, Van Scott, MR, Myrvik, QN and Metzger, WJ. 1998. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J. Immunol., 161: 4283 - 4288.
25. Deknuydt, F, Scotet, E and Bonneville, M. 2009. Modulation of inflammation through IL-17 production by gammadelta T cells: Mandatory in the mouse, dispensable in humans. Immunol. Lett., 127: 8 - 12.
26. McGeachy, MJ, Bak-Jensen, KS, Chen, Y, Tato, CM, Blumenschein, W and McClanahan, T. 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain Th-17 cell-mediated pathology. Nat. Immunol., 8: 1390 - 1397.
27. Mills, KH. 2008. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol., 38: 2636 - 2649.
28. Sutton, CE, Lalor, SJ, Sweeney, CM, Brereton, CF, Lavelle, EC and Mills, KH. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity, 31: 331 - 341.
29. ,s Essential Immunology 12th edition, Hoboken, New Jersey: Blackwell Publishing Ltd.
30. Kalinski, P, Giermasz, A, Nakamura, Y, Basse, P, Storkus, WJ, Kirkwood, JM and Mailliard, RB. 2005. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol. Immunol., 42: 535 - 539.